Known as the brand name anti-epileptic drug Dilantin, Phenytoin has recently piqued the interests of Multiple Sclerosis research and development teams. Study results shared from the National Hospital for Neurology and Neurosurgery in London have been hopeful for patients with MS who were treated with Phenytoin, in response to their cases of acute optic neuritis.[…]
Can Phenytoin Aid the Eyesight of Patients with MS?
Anticonvulsant, Drug Research & Development API, OTC and Compounding Product Tags: MSmultiple sclerosis Jun 04, 2015
Alemtuzumab is a Formidable Therapy for Cancer and Multiple Sclerosis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: MSmultiple sclerosisUnited States Mar 18, 2015
Known as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune[…]
Daclizumab Passes Phase III Hurdles
Immunosuppressant, Monoclonal Antibodies / mAb Tags: MSmultiple sclerosis Jul 03, 2014
Exciting news has been shared by Abbvie and Biogen regarding Daclizumab and it’s now brighter future. The once a month treatment for MS has now cleared all major Phase III hurdles, making a marketing pitch to FDA regulators foreseeable in the near future. As an injectable medication designed to combat the debilitating symptoms of Multiple[…]
Alemtuzumab Approved in Mexico for Multiple Sclerosis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: AlemtuzumabLemtradamultiple sclerosisrelapsing remitting multiple sclerosisRRMS Feb 18, 2014
Exciting news was revealed from Genzyme at the beginning of February 2014, with the announcement that their formidable multiple sclerosis drug, Alemtuzumab, had been approved for use in Mexico. Known as the brand name Lemtrada, Alemtuzumab is specifically effectual for patients with relapsing remitting multiple sclerosis, also coined RRMS. This extremely common and debilitating form[…]
Canada Approves Teriflunomide for Multiple Sclerosis
Anti-Inflammatory, Drug Research & Development API, FDA Approved 2012, Health Canada Approved 2013 Tags: multiple sclerosisrelapsing remitting multiple sclerosisRRMS Dec 06, 2013
On November 22, 2013 Health Canada approved the novel once daily pill Teriflunomide for the treatment of Multiple Sclerosis. Approved by the FDA in September of 2012, this efficacious drug is targeted for treating patients with relapsing remitting multiple sclerosis, or RRMS. The ease of use for this 14 milligram pill, taken only once a[…]
FDA Approves Twice a Day Dose of Dimethyl Fumarate for MS
Immunosuppressant Tags: glatiramer acetateMSmultiple sclerosis Apr 15, 2013
The recent approval of dimethyl fumarate CAS# 624-49-7, on March 27th, 2013, was an encouraging sign for the 2.5 million patients worldwide who are suffering with Multiple Sclerosis. The FDA approved Tecfidera, the brand name for dimethyl fumarate, which is developed by Biogen. As easy to dispense oral capsules, this new treatment for MS is[…]
Shocking Diagnosis of Reality Star Creates a Whirlwind of Attention for Glatiramer Acetate
Drug Research & Development API, Immunological Agent, Patent Expiration 2014 Tags: dexamethasoneglatiramer acetateMSmultiple sclerosis Jun 22, 2012
Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s[…]
Dextromethorphan Hydrobromide Therapy and Usage
Drug Research & Development API, OTC and Compounding Product Tags: Drug Administrationmultiple sclerosis Dec 14, 2010
Dextromethorphan Hydrobromide is a well known cough suppressant drug. During a research study jointly funded by the CIA and the US Navy, Dextromethorphan Hbr was established as a non-addictive substitute for Codeine, a common cough depressant. Codeine is an analgesic, which is addictive in nature. In 1958, the U.S. Food and Drug Administration approved this[…]
